Suchergebnisse - "Payne, Christopher D"

PubPharm (16)

1

A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel : an integrated analysis

enthalten in: Journal of cardiovascular pharmacology | 2010

von Jakubowski, J. | Li, Y. | Small, D. | +4

2

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers : an open-label trial

enthalten in: Clinical therapeutics | 2010

von Small, D. | Payne, C. | Kothare, P. | +12

3

Inhibition of platelet aggregation with prasugrel and clopidogrel : an integrated analysis in 846 subjects

enthalten in: Platelets | 2009

von Li, Y. | Ni, L. | Brandt, J. | +7

4

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects

enthalten in: Pharmacotherapy | 2008

von Farid, N. | Small, D. | Payne, C. | +7

CommentIn: Pharmacotherapy. 2008 Dec;28(12):1423-4. - PMID 19025421

5

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

enthalten in: Current medical research and opinion | 2008

von Small, D. | Farid, N. | Li, Y. | +4

6

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

enthalten in: Platelets | 2008

von Payne, C. | Li, Y. | Brandt, J. | +5

7

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

enthalten in: Journal of clinical pharmacology | 2008

von Small, D. | Farid, N. | Payne, C. | +5

8

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration

enthalten in: Thrombosis and haemostasis | 2008

von Jakubowski, J. | Payne, C. | Li, Y. | +5

9

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry

enthalten in: Thrombosis and haemostasis | 2008

von Jakubowski, J. | Payne, C. | Li, Y. | +5

10

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel

enthalten in: Journal of cardiovascular pharmacology | 2007

von Payne, C. | Li, Y. | Small, D. | +6